Optimizing Histology-Specific Clinical Trials in Soft-Tissue Sarcoma—Are We There Yet?
Mené dans 4 pays européens sur 40 patients atteints d'un liposarcome dédifférencié de stade métastatique ou de stade localement avancé et inopérable, cet essai de phase II non randomisé évalue l'efficacité, du point de vue de la survie sans progression en semaine 12, du cabazitaxel
In the 2022 Annual Report to the Nation on the Status of Cancer in the US, there was an average 1.7% to 2.2% per year improvement in cancer-related mortality over the last 5 years (2014-2018) in 14 of 20 cancers in women and 11 of 19 cancers in men, with melanoma and lung cancer having the biggest decrease in mortality. In contrast, patients with soft-tissue sarcoma had a 0.1% to 0.5% per year decrease in mortality during this same time period. Median overall survival for patients with metastatic dedifferentiated liposarcoma, the most common histologic subtype of soft-tissue sarcoma in adults, remains at about 16 months. First-line therapy for advanced or metastatic liposarcoma centers around doxorubicin-based regimens, but response rates are low (about 20% to 25%) and have remained the same for decades, highlighting the need for novel therapies.
JAMA Oncology 2022